EnVivo Pharmaceuticals Announces Progress On Major Drug Programs Focusing On Alzheimer’s, Schizophrenia And Huntington’s Diseases
Oct 20th 2007Drug InformationAlzheimer's / Dementia News XML/RSS Feed
EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, announced progress on several key programs for addressing Alzheimer’s, Schizophrenia and Huntington’s diseases. EnVivo Pharmaceuticals is developing EVP6124, a selective, orally active Alpha 7 Nicotinic Acetylcholine Receptor Agonist for the treatment of cognitive deficits associated with Alzheimer’s disease and Schizophrenia. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
